Neurotech Pharmaceuticals Appoints Beth Marsh as Chief Commercial Officer

CUMBERLAND, R.I.—Neurotech Pharmaceuticals, Inc., a private biotech company focused on developing therapies for chronic eye diseases, has announced the appointment of Beth Marsh as chief commercial officer, effective April 28. In this role, Marsh will lead the commercial organization, including preparing for the U.S. launch of Encelto (revakinagene taroretcel-lwey), an approved treatment for adults with idiopathic macular telangiectasia type 2 (MacTel), the announcement stated. An established commercial and strategic business executive, the company noted, Marsh brings more than two decades of leadership experience and expertise in ophthalmology and retina.